Pune: Big betting health experts on drugmakers Bharat Biotech vaccine against Covid-19, which is expected to provide protection at the entry point of the virus.
On January 27, the company received regulatory approval to conduct clinical trial phase-3 of the intranasnya vaccine Covid-19 as a booster dose.
The famous virus Dr.
Shahid Jameel told toi that the nose vaccine for respiratory diseases had the advantage of producing antibodies on the surface of the mucosa – the first point of this virus.
“They will be more effective in neutralizing the virus in the entry point than injection vaccines that provide systematic immunity, which can help reduce transmission,” he said.
He said even though the data on the development vaccine was being awaited, his trick would be the right formulation to ensure the delivery of effective vaccine antigens into the mucous immune system.
Another epidemiologist Dr.
Lalit Kant said the intranasal vaccine, as a booster or vice versa, will definitely be a game-changer in the vaccination program.
Intramuscular vaccines provide little or no mucosal immunity, which plays an important role in preventing infection by blocking the entry of viruses in mucosal cells, he said.
Dr.
Kant, who is the former head of the epidemiology and department of infectious diseases in the Indian Medical Research Council (ICMR), said the mucous membrane contains their own immune defense system that fights pathogens, water or food.
When he was challenged, this mucous membrane produced a B cell, which issued an antibody (Iga) Immunoglobulin.
“IGA antibodies work locally on the surface of the mucosa found in the nose, stomach, and lungs,” said Dr.
Kant.
He said the Polio vaccine worked this way, and has brought us closer to the eradication of polyomyelitis.
The measles vaccine given as aerosol, however, is not as effective as injected, he added.
Central Ministry of Health officials and even members of the national task force do not want to do anything on vaccines used in the national immunization program.
“Active trials and will definitely be interesting to see the results,” said a senior health official.
Dr.
Kant said he would be very interested in seeing whether antibodies would be able to neutralize the heterologist virus strain.
Multi-centric clinical trials randomly phase-3 for intranasal vaccines Bharat Biotech will evaluate the nose vaccine for the main schedule of two doses and a booster dose schedule.
According to the company, the intranasal vaccine stimulates a broad immune response – neutralizing IgG, IGA mucosa and cell response T.
Immune response at the location of infection in nasal mucosa is very important for blocking infection and transmission.
“The nose route has a very good potential for vaccination because the immune system is organized from the nasal mucosa,” said a company official.